Want to see RNA full AI Analyst Report?

Atrium Therapeutics, Inc. (RNA) Price & Analysis

11 Followers

RNA Stock Chart & Stats

$14.41

-$0.39(-1.27%)

At close: Jan 08 4:00 PM EST

$14.41

-$0.39(-1.27%)

Day’s Range― - ―

52-Week Range$11.40 - $16.77

Previous CloseN/A

Volume185.29K

Average Volume (3M)2.09M

Market Cap

$209.03M

Enterprise Value-$51.69M

Total Cash (Recent Filing)$267.85M

Total Debt (Recent Filing)$2.68M

Price to Earnings (P/E)―

Beta0.96

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding17,105,642

10 Day Avg. Volume2,820,857

30 Day Avg. Volume2,094,181

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)1.22

Price to Sales (P/S)13.56

P/FCF Ratio-5.93

Enterprise Value/Market Cap-0.25

Enterprise Value/Revenue-1.40

Enterprise Value/Gross Profit0.51

Enterprise Value/Ebitda0.13

Forecast

1Y Price Target

$25.00

Price Target Upside73.49% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Collaboration Revenue DiversificationCollaboration revenues from research partnerships with major pharmaceutical firms contribute to non-dilutive funding and validate external interest in the technology platform.

M&A Deal ProgressAcquisition by Novartis is moving forward with a planned shareholder vote and expected regulatory approvals, supporting a clear path toward deal completion.

SpinCo Capitalization And LeadershipPlanned SpinCo will be capitalized with $270 million in cash and led by the company's Chief Program Officer, providing immediate funding and experienced leadership for independent development.

Bears Say

Analyst Risk DesignationAnalyst's Neutral rating with a High Risk designation highlights limited upside expectations and deal-related uncertainty that could pressure the stock.

Reduced Ownership In Cardiology AssetsAtrium's sole ownership of precision cardiology applications reduces the company's stake in cardiology programs and may limit future upside from those assets.

Atrium Therapeutics, Inc. News

Atrium Therapeutics announces FDA clearance of ATR 1072 IND application

Atrium Therapeutics (RNA) announced that the FDA has cleared its investigational new drug, or IND, application allowing the...

1d ago

RNA

Atrium Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Atrium Therapeutics (RNA) with an Overweight rating and $25 price target Atrium’s RNA...

27d ago

RNA

Atrium Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Atrium Therapeutics (RNA) with an Overweight rating and $25 price target Published first...

27d ago

RNA

Leerink starts ‘interesting preclinical-stage opportunity’ Atrium at Outperform

Leerink initiated coverage of Atrium Therapeutics (RNA) with an Outperform rating and $25 price target calling the company...

2M ago

RNA

Atrium Therapeutics initiated with an Outperform at Leerink

Leerink initiated coverage of Atrium Therapeutics (RNA) with an Outperform rating and $25 price target Published first on...

2M ago

RNA

Trump Trade: U.S. plans AI security order without required model tests

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

2M ago

DYN

RNA

Trump approves plan to fire FDA head Marty Makary, CBS reports

President Trump has approved a plan to fire Food and Drug Administration Commissioner Marty Makary, Kristin Brown and...

2M ago

DYN

RNA

Atrium Therapeutics earns $15M development milestone payment from Bristol Myers

Atrium Therapeutics (RNA) has earned a $15M development milestone payment from Bristol Myers (BMY). The milestone was achieved...

3M ago

BMY

RNA

Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says

Houman Hemmati, an ophthalmologist, biotech executive and frequent Fox News guest, is a candidate to become the next...

3M ago

DYN

RNA

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: ProShares UltraShort Lehman 20...

4M ago

MUB

NFE

RNA Earnings this Week: How Will it Perform?

Avidity Biosciences Inc (RNA) is scheduled to report 4th quarter earnings on 03/03/2026. Regarding Q4 estimates, Wall Street...

5M ago

RNA

Morning News Wrap-Up 2/27/26: Today’s Biggest Stock Market Stories!

Traders will find the best stock market stories to read on Friday in our daily wrap-up. ...

5M ago

DIA

RNA

Avidity Biosciences Completes Merger and Plans Nasdaq Delisting

Avidity Biosciences ( ($RNA) ) has issued an update. Following the closing of a previously agreed merger, Avidity...

5M ago

RNA

Why Is Avidity Biosciences Stock (RNA) Down Today?

Avidity Biosciences stock appeared to take a beating on Friday following a deal with Novartis. ...

5M ago

NVS

RNA

RNA FAQ

What was Atrium Therapeutics, Inc.’s price range in the past 12 months?

Atrium Therapeutics, Inc. lowest stock price was $11.40 and its highest was $16.77 in the past 12 months.

What is Atrium Therapeutics, Inc.’s market cap?

Atrium Therapeutics, Inc.’s market cap is $209.03M.

When is Atrium Therapeutics, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Atrium Therapeutics, Inc.’s earnings last quarter?

Currently, no data Available

Is Atrium Therapeutics, Inc. overvalued?

According to Wall Street analysts Atrium Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Atrium Therapeutics, Inc. pay dividends?

Atrium Therapeutics, Inc. does not currently pay dividends.

What is Atrium Therapeutics, Inc.’s EPS estimate?

Atrium Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Atrium Therapeutics, Inc. have?

Atrium Therapeutics, Inc. has 17,105,642 shares outstanding.

What happened to Atrium Therapeutics, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Atrium Therapeutics, Inc.?

Currently, no hedge funds are holding shares in RNA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Atrium Therapeutics, Inc. Stock Smart Score

Neutral

Company Description

Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.

Atrium Therapeutics, Inc. (RNA) Earnings & Revenues

Historic Earnings Reports

RNA Stock 12 Month Forecast

Average Price Target

$25.00

▲(73.49% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","26":"$26","14.75":"$14.75","18.5":"$18.5","22.25":"$22.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,14.75,18.5,22.25,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.3,14.200000000000001,15.100000000000001,16,16.9,17.8,18.7,19.6,20.5,21.4,22.3,23.2,24.1,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.3,14.200000000000001,15.100000000000001,16,16.9,17.8,18.7,19.6,20.5,21.4,22.3,23.2,24.1,{"y":25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.3,14.200000000000001,15.100000000000001,16,16.9,17.8,18.7,19.6,20.5,21.4,22.3,23.2,24.1,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.75,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.75,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.75,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.75,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.75,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":14.75,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":14.75,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":14.75,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":14.91,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.47,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.43,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.68,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.3,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >